ATAI ATAI Life Sciences
- 2.111
- +0.061+2.98%
ATAI Life Sciences News
Express News | Atai Life Sciences Disclosed Dosing Of First Patient In Part 2 Of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive To SSRIs In Patients With Treatment Resistant Depression
Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
ATAI Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the publication of the
Atai Life Sciences CEO Florian Brand Spotlights Psychedelic Therapy Milestones and Upcoming Catalysts | NASDAQ:ATAI, ETR:9VC
ATAI Life Sciences(ATAI.US) Officer Sells US$66,231.85 in Common Stock
$ATAI Life Sciences(ATAI.US)$ Officer Kirpekar Sahil sold 35,801 shares of Common Stock on Apr 2, 2024 at an average price of $1.85 for a total value of $66,231.85.Source: Announcement What is stateme
ATAI Life Sciences(ATAI.US) Officer Sells US$50,708.5 in Common Stock
$ATAI Life Sciences(ATAI.US)$ Officer Johnson Anne Nagengast sold 27,410 shares of Common Stock on Apr 2, 2024 at an average price of $1.85 for a total value of $50,708.5.Source: Announcement What is
ATAI Life Sciences(ATAI.US) Officer Sells US$114.03K in Common Stock
$ATAI Life Sciences(ATAI.US)$ Officer Rao Srinivas sold 61,640 shares of Common Stock on Apr 2, 2024 at an average price of $1.85 for a total value of $114.03K.Source: Announcement What is statement o
Express News | Cantor Fitzgerald Reiterates Overweight on ATAI Life Sciences
Form 144 | ATAI Life Sciences(ATAI.US) Officer Proposes to Sell 228.03K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 3, $ATAI Life Sciences(ATAI.US)$ Officer STEPHEN BARDIN intends to sell 107.05K shares of its common stock on Apr 3, with a total market value of approximately $228.03K.
NASDAQ New 52-Week Highs And Lows
New Highs 103 COMPANY SYMBOL HIGH VOLUME ------- ------ ---- ------ ARCA biopharma ABIO 3.88 73,832,960
Atai Life Sciences Upgraded at Maxim on Beckley Investment
Express News | ATAI Life Sciences Shares Are Trading Higher After Maxim Group Upgraded the Stock From Hold to Buy and Announced a $6 Price Target
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. Shares of Signet Jewelers Limited (NYSE:SIG) rose sharply during Wednesday's session after the company raised its FY25
ATAI Life Sciences Raised to Buy From Hold by Maxim Group
ATAI Life Sciences Raised to Buy From Hold by Maxim Group
Express News | Maxim Group Upgrades ATAI Life Sciences to Buy, Announces $6 Price Target
SLS, IBIO and ALDX Are Among Premarket Gainers
ATAI Life Sciences Is Maintained at Buy by HC Wainwright & Co.
ATAI Life Sciences Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on ATAI Life Sciences, Lowers Price Target to $15
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionPartners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a P
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
Clinical-stage psychedelics biotech Atai Life Sciences (NASDAQ:ATAI) announced its consolidated financial results for the fourth quarter and full year 2023.The Numbers:Cash, cash equivalents and short
Analysis
Price Target
No Data
